Upstream Bio, Inc. (UPB) is a Healthcare · Biotechnology company listed on NASDAQ. Price $5.34 (+0.56%), Market cap $0.49B, 52-week low–high $7.36 ~ $32.60.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease. The company was incorporated in 2021 and is headquartered in Waltham, Massachusetts.
Financial statements, price targets, institutional (13F) holdings and related news for Upstream Bio, Inc. are updated in real time on BlackAll Trade.
Upstream Bio, Inc. trades at $5.34 (+0.56%). Real-time quotes and charts are available on BlackAll Trade.
Upstream Bio, Inc. has a market cap of about $0.49B.
Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for